BridgeBio Pharma Inc (BBIO) concluded trading on Wednesday at a closing price of $45.98, with 4.63 million shares of worth about $213.05 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 63.51% during that period and on July 09, 2025 the price saw a gain of about 6.46%. Currently the company’s common shares owned by public are about 189.83M shares, out of which, 160.86M shares are available for trading.
Stock saw a price change of 7.48% in past 5 days and over the past one month there was a price change of 19.06%. Year-to-date (YTD), BBIO shares are showing a performance of 78.49% which increased to 67.57% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $21.72 but also hit the highest price of $45.48 during that period. The average intraday trading volume for BridgeBio Pharma Inc shares is 3.09 million. The stock is currently trading 8.45% above its 20-day simple moving average (SMA20), while that difference is up 20.22% for SMA50 and it goes to 43.74% higher than SMA200.
BridgeBio Pharma Inc (NASDAQ: BBIO) currently have 189.83M outstanding shares and institutions hold larger chunk of about 83.87% of that.
The stock has a current market capitalization of $8.73B and its 3Y-monthly beta is at 1.23. It has posted earnings per share of -$3.53 in the same period. It has Quick Ratio of 4.54. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BBIO, volatility over the week remained 3.27% while standing at 3.60% over the month.
Stock’s fiscal year EPS is expected to drop by -1.83% while it is estimated to increase by 44.09% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Oppenheimer on July 09, 2025 offering an Outperform rating for the stock and assigned a target price of $60 to it. Coverage by Wolfe Research stated BridgeBio Pharma Inc (BBIO) stock as an Outperform in their note to investors on June 17, 2025, suggesting a price target of $49 for the stock. Stock get a Perform rating from Oppenheimer on October 03, 2024.
